Dermatology

The primary endpoint analyses from the SUNSHINE and SUNRISE Phase III trials of secukinumab in moderate-to-severe hidradenitis suppurativa (HS) were featured in an oral presentation as part of the late-breaking news session at the 31st annual European Academy of Dermatology and Venereology (EADV) congress. Known collectively as the SUNNY trials, the SUNSHINE and SUNRISE studies represent the largest Phase III trials conducted in HS to date.

Any filler injection requires a bespoke treatment approach and a thorough anatomy knowledge to minimise procedural risks and achieve…

The solar spectrum is composed of various wavelengths of electromagnetic radiation that can penetrate the skin to different levels: the longer…

The latest research on autoimmune skin disease has studied the efficacy and safety characterisation of guselkumab (GUS), a human monoclonal…

Strober began by summarising his opinion on the key characteristics of anti-IL-23 therapies that support their efficacy for inducing…

The latest international guidelines on urticaria were published in September as a joint initiative from the European Academy of…

Recent years have witnessed significant advances in the understanding of facial anatomy. Extensive studies have uncovered the arrangement of soft-tissue layers underlying the skin and their mobility during expression. Meanwhile, increasing awareness of the facial vascular network has laid the foundation for lower risk cosmetic procedures.

Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…